This Psychedelics Stock Could Grow 300% In One Year

Experts predict major growth for this psychedelics stock.

Last week, the financial services firm Cantor Fitzgerald initiated coverage of Cybin Inc. (CYBN).

The stock was just $2.25 per share when the firm gave Cybin a 12-month price target of $9  – a 300% margin.

The analysts believe that Cybin’s proprietary formulation for treating depression which is in phase 2 clinical trials, has great potential for scalability. They explain that Cybin has enough capital to advance its other formulations for anxiety and alcohol use disorder through clinical trials as well.